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These alterations eventually impair the capacity of MBF 
to adapt to changes in myocardial oxygen demand.
Structural abnor ali ies responsible for the develop-
ment of CMD are consistently documented in patients 
with hypertrophic cardiomyopathy and those with arterial 
hypertension. In both these conditions, the morphological 
changes observed are characterized by adverse remodel-
ling of intramural coronary arterioles, resulting in medial 
wall thickening (mainly owing to smooth muscle hyper-
trophy and increased collagen deposition) and variable 
degrees of intimal thickening (Figure 2). The remodelling 
of intra mural coronary arterioles is the anatomical sub-
strate underlying the abnormal coronary physiology and 
blood flow in patients with arterial hypertension or hyper-
trophic cardiomyopathy (although qualitatively similar in 
the two conditions, these changes are usually more exten-
sive in patients with hypertrophic cardiomyopathy).2 An 
important feature common to both patients with arterial 
hypertension and those with hypertrophic cardiomyo-
pathy is the diffuse nature of microvascular remodelling, 
which extends to the entire left ventricle.6 Structural abnor-
malities of the coronary microcirculation have also been 
described in other clinical conditions (Box 1).
CMD can be sustained by a combination of func-
tional mechanisms that lead either to impaired dilata-
tion or increased constriction of coronary microvessels 
(Figure 3; Box 1). Impaired vasodilatation can result 
from abnormalities in endothelium-dependent mecha-
nisms associated with diabetes mellitus, obesity, tobacco 
smoking, and other cardiovascular risk factors, as well as 
impairment of endothelium-independent mechanisms, 
such as the development of nitrate resistance owing to 
reduced production of cyclic GMP.7 Evidence of myo-
cardial ischaemia related to microvascular constriction 
in humans comes from a few studies involving intra-
coronary injection of either neuropeptide Y8 or high 
doses of acetylcholine.9,10 In patients with normal coro-
nary arteries, these agents can cause chest pain and objec-
tive evidence of myocardial ischaemia in the absence of 
relevant changes to epicardial coronary arteries. The 
functional responsiveness of the microcirculation can 
be influenced by several factors, such as increased heart 
rate, reduced diastolic time, decreased driving blood 
pressure, and left ventricular inotropism, which need to 
be  considered when assessing microvascular function.3,11
During the cardiac cycle, the pulsatile pattern of 
coronary blood flow follows the physiological varia-
tions induced by changes in intramyocardial and intra-
ventricular press res occurring during systole and diastole 
(Figure 4).7 Given that flow mainly occurs in diastole, 
abnormalities in this phase of the cardiac cycle have a 
strong effect on myocardial perfusion. Nevertheless, 
an increase in systolic intramyocardial and ventricular 
pressures, as typically occurs in primary and secondary 
left ventricular hypertrophy, can also adversely affect 
m yocardial perfusion.12–14
Assessment of coronary microcirculation
Currently, no technique allows direct visualization of the 
coronary microcirculation in vivo in humans. Coronary 
Key points
 ■ Prearterioles (100–500 μm in diameter) and arterioles (<100 μm in 
diameter, the site of metabolic regulation of myocardial blood flow) make  
up the coronary microcirculation
 ■ In the past 2 decades, coronary microvascular dysfunction emerged as an 
important mechanism of myocardial ischaemia
 ■ Coronary microvascular dysfunction can result from functional and/or structural 
alterations, the relative importance of which seems to vary across clinical 
settings; several such alterations can also coexist in one condition
 ■ No technique can visualize the coronary microcirculation in vivo in 
humans; microvascular function is, therefore, assessed indirectly, through 
measurements of coronary or myocardial blood flow and coronary flow reserve
 ■ Several invasive and noninvasive techniques can be used to assess 













































Conductive vessels Prearteriolar vessels Arteriolar vessels
Figure 1 | Coronary arterial circulation. The coronary arterial system comprises 
large conductive vessels and the microcirculation (prearterioles and arterioles). 
The drop of pressure relative to that in the aorta is negligible in conductive 
vessels. By contrast, a considerable pressure drop occurs through prearterioles, 
and, to a larger extent, through arterioles. Conductive vessels and (to an even 
greater extent) proximal prearterioles are most responsive to flow-dependent 
dilatation. Distal prearterioles are most responsive to changes in intravascular 
pressure, and are mainly responsible for autoregulation of coronary blood flow, 
whereas arterioles are most responsive to changes in the intramyocardial 
concentration of metabolites, and are mainly responsible for the metabolic 
regulation of coronary blood flow. Permission obtained from Oxford University 
Press © Crea, F. et al., Chronic ischaemic heart disease. In The ESC Textbook of 
Cardiovascular Medicine 2nd edn (eds Camm, A. J. et al.) Figure 1, Ch. 17, 599 
(Oxford University Press, 2009).
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Atherosclerotic epicardial plaques have a complex relation
to coronary resistance. Some of these (20–30%) are dynamic,
albeit within a reasonably small range of reactivity where
exercise or constricting agents may induce a 20% reduction in
the stenosis diameter. Others, however, appear to be fixed. In
addition, the longer the coronary lesion the greater the
resistance and, of course, two lesions in parallel add further
to stenosis significance.
The assessment of the relation between the degree of
epicardial coronary narrowing and the measured coronary
flow reserve is complex and generalisations are difficult.
Within instrumented animals the classic work of Gould and
Lipscomb in the 1970s suggests that a stenosis in a conduit
vessel of less than 50% is unlikely to be of haemodynamic
significance.9 For stenoses with luminal narrowing greater
than 50% there is a complex and curvilinear relation to the
reduction in maximum coronary flow. Lesion length also
affects the coronary flow reserve, with longer lesions
producing greater haemodynamic ch ges.10
Assessment of coronary stenosis and impact on
coronary flow
Assessments of patients by angiography have, in general,
shown a very imprecise relation between the degree of
coronary narrowing and coronary flow reserve.11 12 However,
the use of positron emission tomography (PET) scanning to
measure coronary flow reserve has increased our ability to
measure this difficult parameter accurately under basal
conditions in humans.13 These studies have confirmed a
complex relation, again curvilinear, between coronary ste-
nosis diameter and coronary flow reserve, but it should be
noted that the individual points for patients studied show
remarkable scatter around any statistically defined relation.
Nonetheless the PET data would not wildly disagree with the
animal data indicating that stenoses less than 50% in
diameter are unlikely to be of functional haemodynamic
significance.
The advent of intracoronary wires able to carry Doppler and
pressure transducers has allowed cardiologists to ‘‘interro-
gate’’ epicardial coronary stenoses that appear to be of
borderline significance. It is not possible within this article to
review these in detail. Broadly, however, these devices all rely
on the induction of maximal hyperaemia with a micro-
vascular vasodilating drug (usually adenosine) administered
either intravenously or intracoronary. Devices either record
the change in coronary blood velocity (Doppler wires) or
measure the pressure gradient induced across the lesion
(pressure wires, RADI). Doppler wires, because of technical
considerations and the influence of side branches and the
variability of signal if moved, have been largely an experi-
mental tool. The pressure wire appears more stable and is
easier to use. The important work of Pijls in this area has
suggested that a ratio of mean distal coronary blood pressure
to me proximal coronary blood pressure following max-
imum hyperaemia of less than 0.75–0.8 indicates a stenosis
that is of func ional significance.14
Widely dynamic epicardial coronary stenosis and
Prinzmetal’s variant angina
A small percentage of usually mild coronary stenoses display
intense vasoconstrictive responses.15 Such constriction may
be to a degree sufficient to occlude the epicardial coronary
entirely, and under these circumstances ST elevation may
arise. This is the pathological basis of so-called Prinzmetal’s
variant angina.16 This diagnosis usually manifests itself by the
complete resolution of ST elevation by the administration of
nitrates or, in the catheter room, by the complete disap-
pearance of an epicardial coronary stenosis following the
administration of intracoronary nitrates. Specialist centres
Figure 1 The sigmoid line shows resting coronary blood flow which
has an aut regulated range at physiological pressure. Following
metabolic demands the coronary circulation undergoes vasodilatation
which wh n maximal becom s a pr ssure driv syst m (the oblique
straight line). The difference between the two lines is the coronary flow
reserve which is a variable parameter depending on the perfusion
pressure.
Figure 2 Resistance to coronary flow is seen in two compartments.
Normal epicardial coronary arteries are conduit vessels offering
virtually no resistance to flow. The pre-arteri lar segments (,300–
100 mm) offer variable resistance to flow and are regulated by a
number of factors including nitric oxide. The arteriolar segment
(, 100 mm) offers the greatest amount of resistance to flow and is the





















agents. Importantly, patients reported better tolerance
with regadenson with fewer side effects during admin-
istration.4 Recently the ADVANCE MPI 2 trial, a
substudy of ADVANCE-MPI, observed no significant
differences in defect size produced by adenosine and
regadenoson using quantitative analysis.5 In summary,
regadenoson is equivalent to adenosine for detection of
ischemia with a more tolerable side effect profile.
CLINICAL APPLICATION OF REGADENOSON
Dipyridamole and adenosine are both administered
via a weight-based, continuous infusion due to the short
half lifes of these agents. Regadenoson has a longer half-
life facilitating bolus injection, and the selective recep-
tor affinity obviates the need for weight-based dosing
and the use of an infusion pump. Regadenoson is sup-
plied in a 5 cc pre-filled syringe for administration via a
bolus injection of 400 mcg over 10 s followed by a 5 cc
saline flush. Radiotracer is then injected 10-20 s later
followed by standard imaging.6 Regadenoson increases
coronary blood flow 2.5-fold over baseline for a period
of 2-3 min. This degree of hyperemia has been shown in
both animal and human models to be comparable to
the effect of intravenous administration of adenosine.7,8
The primary hemodynamic effects of regadenson at the
standard dose are an increase in heart rate (mean max
increase 21 bpm ± 21) and a decrease in blood pressure
(SBP—24 mmHg ± 16, DBP—12 mmHg ± 10). The
administration of aminophylline (25-100 mg, slow
intravenous injection) is effective in abbreviating the
coronary vasodilatory response to regadenoson, but not
its heart rate response.8 The most common side effects
associated with regadenoson include dyspnea (28%),
headache (26%), flushing (16%), chest discomfort
(13%), angina pectoris or ST depression (12%), dizzi-
ness (8%), chest pain (7%), nausea (6%), abdominal
discomfort (5%), dysgeusia (5%), and a sensation of
warmth (5%). Patients in the ADVANCE-MPI studies
reported fewer subjective symptoms when compared
with intravenous adenosine. Major adverse reactions,
such as high-grade AV block or severe bronchospasm,
were not reported in these trials though it should be
noted that patients at high risk for these events were
Figure 1. Adenosine receptor subtypes, mechanisms of action and clinical effects. Pharmacologic
stress testing with vasodilators increases adenosine concentrations either indirectly through
dipyridamole administration (reduced facilitated transport of adenosine into cell) or via exogenous
adenosine administration. Caffeine, aminophylline and theophylline act as nonselective competitive
adenosine inhibitors and counteract its downstream effects. Adenosine activates all four receptor
subtypes (A1, A2A, A2B, and A3). Two of these subtype receptors, A2A and A2B activate adenylate
cyclase resulting in increased cyclic AMP production resulting in activation of protein kinase, and
stimulation of KATP channels resulting in hyperpolarization of smooth muscle cells and consequent
relaxation (vasodilation). Adenosine also inhibits entry of calcium into cells via L-type calcium
channels resulting in the same endpoint. A1 and A3 receptors counteract these effects to a lesser
degree by reducing adenylate cyclase activity. Listed at the right are the systemic side effects
mediated by the four receptor subtypes.
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further honed if certain patient subsets within our cohort of con-
secutive patients would, on clinical grounds, be excluded.
However, this approach serves to introduce bias and undermines
both the internal and external validity of the study. In this trade-off,
we chose to protect validity at the cost of potentially obfuscating
the clinical message and possibly introducing statistical noise into
our comparison.
It is possible that not all patients with chest pain referred to
testing and later found not to have CAD (e.g. valve disease, cardi-
omyopathy) were identified and excluded. However, as these
patients are less likely to manifest ischaemia, and are likely to be
treated medically, we would anticipate that their presence in any
significant numbers would inflate the medical therapy mortality
rate in patients without ischaemia. This would serve to decrease
the survival advantage of medical therapy over revascularization
in the setting of little or no ischaemia.
Although the impact of selection biases, spurious observations,
and unmeasured covariates cannot be ignored, patients in observa-
tional studies better represent those see in practice and, unlike
randomized clinical trials (RCTs), can account for changes in
therapy over time. However, the results of this and all other obse -
vational studies constitute hypothesis generating findings that,
ideally, may spur on further investigations, preferably with random-
ized methodologies. Whether a survival benefit definitively exists
at any level of ischaemia can only be answered by an RCT.
Further, limitations associated with multivariable techniques
(including propensity scores) applied to observational data to
adjust for potential confounding have been characterized.19
The current study was designed as an effectiveness study in that
the treatment received by patients was dictated by the clinical
practice of their physicians. Thus, ‘medical therapy’ after MPS
was defined as that treatment received in the absence of referral
to revascularization but the nature of medical therapy was
unknown. Both medical therapy and the type of revascularization
used are likely to be ‘under-treatment’ relative to today’s rec-
ommendations, as these patients were tested in an era prior to
the development of many therapeutics used routinely today.
That said, the current use of post-imaging therapeutics—catheter-
ization referral and medical therapy—is far less than expected, and
30–45% of patients are not on guideline indicated medications
after the finding of extensive abnormalities on imaging.21,22 None-
theless, whether such medications were given and to whom is not
known in our data. Also, we did not differentiate in the current
analysis between revascularizations performed with CABG vs.
PCI. Recent studies suggest that the efficacy of these two
approaches may differ in select patient subgroups, hence, the
addition of this component to our analysis may have identified
inter-treatment differences.23
The current study is limited by the use of all-cause mortality as
the primary endpoint. Although this approach limits potential mis-
classification bi s associated with the assignment of caus of death,
it is also limited in that the interventions we assess impact cardiac
death far more than all-cause mortality. The US Social Security
Death Index was used to identify deaths occurring on long-term
follow-up. It is possible that we ‘missed’ events due to deaths
occurring outside of the US or to the ‘lag period’ between time
of death and its appearance in the death index. Hence, it is possible
that a misclassification bias exists in ‘missing’ deaths that occurred
very late in the follow-up period. However, we believe the number
of deaths missed is relatively few.
The current study utilized a 20-segment scoring model and the
summed defect scores converted to %myocardium. Compared
with the 17-segment system, this approach is hampered by over-
weighting of the apical segments. Hypothetically, this may result
Figure 4 Log hazard ratio for revascularization vs. medical therapy as a function of %myocardium ischaemic in patients with ,10% ischaemic
myocardium. Graphic representation based on Cox proportional hazards mod l. Interaction P, 0.001.
R. Hachamovitch et al.Page 10 of 13
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Figure 1.3. Diagnostic accuracy by contrast agent dose. 
Gadodiamide doses ranging from 0.01 to 0.1 mmol/kg in the MR-IMPACT study. 
Reproduced from (Schwitter et al., 2008). 
 
1.3.1.3 Contrast Dose and Signal Intensity Linearity 
Semi-quantitative and fully quantitative methods of myocardial perfusion analysis 
ideally require a linear relationship between contrast concentration and signal intensity. 
With gadolinium-based contrast media, this relationship only approaches linearity at 
low concentrations, above which the signal intensity response flattens non-linearly 
(Figure 1.4). The flattening can be attributed to the T1 shortening effect of gadolinium 
which, as the gadolinium concentration increases beyond a particular level, may lead to 
complete recovery of longitudinal magnetisation in the period between the saturation 




and the images are read out with several radiofrequency
excitations/echo trains.23 This results in a 30% to 40%
speed advantage compared with conventional GRE
sequences and is particularly useful at field strengths of
1.5 T or lower. (At 3.0 T and higher, any increase in TE
beyond the minimum allowed by the gradient system
nearly inevitably gives rise to susceptibility artifacts, in par
ticular, during passage of a contrast bolus.)
The signal to noise ratio and the contrast to noise ratio
in GRE images are relatively low, when a short TR and wide
receiver bandwidths are used. The maximum signal inten
sity is reached with relat vely low flip angles. (The flip
angle corresponding to maximum signal intensity is
referred to as Ernst angle.) To overcome this limitation,
one can use an ingenious scheme, referred to as SSFP, to
preserve the cohere ce of the transverse magnetizatio
between TRs in the pulse sequence and efficiently convert
magnetization between transverse and longitudinal orienta
tions. With SSFP, the Ernst angle can approach 90! (i.e.,
one can reach the maximum theoretical signal amplitude
after each radiofrequency excitation while still repeating
the excitations with very short TRs). In fact, the TRs should
be as short as feasible because the susceptibility of the SSFP
technique to any off resonance shifts increases with TR
and also with flow.24 Off resonance frequency shifts result
in dark bands at locations where the frequency shift (in
radians per second) times TR (in seconds) equals an odd
multiple of p/2. Herein lies the Achilles heel of the SSFP
technique, and not surprisingly, the passage of a contrast
bolus can exacerbate frequency shifts and artifacts. As
absolute frequency shifts increase with field strength
(assuming the same relative field homogeneity at different
field strengths), one can best reap the advantages of SSFP
techniques for perfusion imaging at field strengths of up
to 1.5 T. Because of the relatively good signal to noise ratio,
the SSFP techniques can produce more appealing image
quality,25 but the use of the SSFP technique for myocardial
perfusion imaging must be approached with caution
because the artifacts on SSFP images can be deceptive
and mimic hypoperfusion.
Ultrafast T1 measurements would provide the most
accurate estimates of contrast agent concentration, and
with the advent of ar llel imaging, this approa h may
become practical. Chen and coworkers developed such a
T1 fast acquisition relaxation mapping (T1 FARM) method
to obtain single slice T1 maps of the heart with 1 sec reso
lution.26,27 With direct measurement of T1, the problems
associated with the saturation of the signal with increasing
contrast agent dosage can be avoided. This should allow for
more accurate quantification of blood flow with usage of
higher contrast agent dosages. Figure 4 2 shows two signal
curves for a region of interest in the left ventricle measured
during bolus injection of 0.075 mmol/kg gadolinium
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Figure 4 1 The gradient echo cardiovascular magnetic resonance images show the first pass of an extracellular contrast agent (0.03 mmol/kg
Omniscan, GE Healthcare Princeton, NJ) in a healthy volunteer, with appearance of the contrast first in the right ventricle (RV), followed by the
left ventricle (LV), and finally leading to myocardial contrast enhancement. The contrast agent was injected after acquisition of approximately
four pre contrast images. Images were acquired in the short axis view at the level of the papillary muscle. The arrows show the correspondence
between images and the time course of changes in signal intensity for a region of interest in the left ventricle (solid circles) and a myocardial
segment in the posterior wall (diamonds). Characteristics of the signal curve for a tissue region, such as its increased dispersion, lower
amplitude, and reduced rate of signal enhancement compared with the ventricle, result from transit through the coro ry microcirculation,




































injection, an arguably acceptable level for the background
signal increase in the blood pool. In the myocardium, the
signal intensity level at 10 minutes after contrast injection
is only ~10-20% higher than before contrast injection,
which is a small fraction of the peak myocardial contrast
enhancement during a first pass. After 10 minutes or
longer, the background signal is therefore unlikely to
make a significant contribution to signal saturation effects,
which is arguably the primary concern related to the
contrast residue from a previous injection. Higher contrast
dosages may require longer delays before a repeat
injection.
An important question is whether one wants to treat
the vascular space as spatially lumped compartment
(“well-stirred tank”) with a uniform concentration of
contrast, or whether one accounts for the fact that a
vascular element has a spatial extent and the concentra-
tion of tracer can be higher at the arterial inlet(s) than
further downstream. The latter approach results in a
spatially dependent concentration of tracer or contrast.
Mathematically this translate into the introdu tion of
(a) spatial variable(s) into the set of (differential) equa-
tions that describe the tissue model, in addition to the
time variable t, that describes the variation of contrast
concentration with time. The compartmental model
without spatial variable(s) only considers the change of
contrast concentration as a function of time, and is
termed a lumped compartment model. A prototypical
example of a lumped two-compartment model is shown
in Figure 3. The neglect of the spatial concentration gra-
dients can result in an underestimati n of the comp t-
mental volumes, which can be verified by simulations
where all parameters except the length of an axially-
distributed blood-tissue exchange unit are kept constant.
If the total distribution volume, including the vascular
volume, is kept fixed for fitting of myocardial signal
intensity curves to a model, then a lumped compart-
m nt model will sult in an ov restimate of bloo flow,
compared to a spatially distributed model. Using a spa-
tially distributed model instead of a spatially lumped
model can therefore have a significant positive impact
on the accuracy of blood flow estimation.
For an extracellular contrast agent an important contri-
bution to the total observed or measured tissue contrast
concentration comes from the fraction of contrast that
has traversed the capillary barrier and leaked into the
interstitial space [35]. On signal intensity curves from
myocardial perfusion studies the difference becomes
clearly visible in the form of elevated signal intensity after
the first pass of the contrast: contrast has passed into the
interstitial space, and although it will eventually return to
the vascular space and be washed out of the tissue region,
Figure 2 The characteristics of myocardial contrast enhancement. The characteristics of myocardial contrast enhancement have been
assessed in the literature using several parameters, as illustrated in this example, showing the signal intensity changes in the LV blood pool
(arterial input function ℵ AIF), and in an anterior segment of the left ventricle (green circles). The blue line shows the fit to the measured data
with a two-space distributed model. The dashed red line is commonly referred to as the up-slope parameter, and gives the initial rate of
contrast enhancement. It is often normalized by the up-slope of the AIF, as an empirical correction factor to account for hemodynamic changes
between rest and stress. The area under the tissue curve (gray shaded area), up to the location in time where the peak of the AIF is observed,
has been proposed as an alternative parameter to assess perfusion and the perfusion reserve. The myocardial peak signal intensity during the
first pass of the contrast bolus in the LV is arguably the least flow-sensitive parameter, and therefore only used to assess contrast-to-noise, but
not changes or differences in myocardial perfusion.
Jerosch-Herold Journal of Cardiovascular Magnetic Resonance 2010, 12:57
http://www.jcmr-online.com/content/12/1/57






Figure 1.4. Relationship of signal intensity to contrast dose.  
Maximal contrast enhancement with varying doses of contrast agent during CMR MPI 
using TurboFLASH and EPI sequences. Reproduced from (Utz et al., 2007) 
(MCE norm – Normalised maximal contrast enhancement, bw – bodyweight) 
 
In the dual bolus technique (Christian et al., 2004), the first contrast bolus is a low dose 
(typically 0.0025-0.005mmol/kg) allowing accurate assessment of the arterial input 
function from the LV blood pool. The second dose is higher (0.05-0.1mmol/kg), 
allowing a visual and quantitative assessment of myocardial perfusion. In the dual 
sequence method (Gatehouse et al., 2004), an additional low-resolution short 
saturation-recovery time image is acquired during each cardiac cycle to permit the 







17	Fermi	function	deconvolution.	Reproduced	from	(175).	The	myocardial	time-intensity	curves	(TIC)	(left)	equal	the	bloodpool	TIC	(middle)	convolved	with	the	Fermi	transfer	function.	The	maximal	amplitude	of	the	transfer	function	equals	absolute	myocardial	blood	flow.	The	areas	between	the	dashed	lines	of	the	TICs	are	used	for	analysis;	these	have	also	been	corrected	for	coil	effects,	baseline	signal	intensity	and	conversion	to	gadolinium	concentration.		technique (17) injects 2 boluses, an initial minibolus
that maintains blood pool linearity followed by a large
bolus that maximizes myocardial SNR (18).
It had been assumed, because myocardial CMR
signals were much less than blood pool signals, that
nonlinearity was not an issue within the myocar-
dium. However, a growing body of evidence sug-
gests that myocardial nonlinearity becomes signifi-
cant at bolus concentrations necessary for sufficiently
high myocardial SNR (19–21). This effect might be
due to incomplete extraction of GdCA from the
vascular space, limiting the proportion of myocar-
dial protons with which gadolinium can interact.
The optimal solution to this nonlinearity has not
yet been defined, although converting the CMR
signal into gadolinium concentration (19,21) or
correcting the signal with algorithms based on the
theoretical signal response to gadolinium (22,23)
might be feasible options.
Another assumption in the LSI model is that the
input function can be accurately measured. For con-
venience, the input TIC is taken from the LV blood
pool in the short axis. However, this bolus undergoes
further mixing and dispersion before reaching the
coronary arteries, a phenomenon better appreciated in
quantitative cerebral perfusion (24). Additionally, the
presence of collateral flow alters the input function
seen by a region of myocardium (25). These effects
need to be minimized or accounted for when specify-
ing the input time-intensity curve.
The specific validity of the Fermi deconvolution
model is challenged by several deviations from its
assumptions. First, the tracer bolus recirculates, and
thus its “first-pass” contains some of the second-
pass as well. Although recirculation does not violate
the assumptions of an LSI system, it does demand
a more complex transfer function than that offered
by the Fermi model. Alternatively, recirculation can
be modeled and subtracted from the time-intensity
curves to remove its effects (26). Second, most clini-
cally approved GdCA do not remain exclusively
within the intravascular space, but leak into extravas-
cular compartments. Again, this leak does not violate
LSI assumptions, but the Fermi transfer function
cannot accommodate it. Finally, the presence of col-
laterals requires a more complex shape to the transfer
function than allowed by the Fermi model (25).
To overcome these limitations, a more complex
constrained deconvolution model termed “model-
independent” (although it is itself a parameterized
model) has been proposed (27). This builds a
transfer function from splines and uses sophisti-
cated mathematical techniques to produce a more
intricate curve while not overfitting noise within the
data. However, its use has not become widespread,
likely due to its mathematical complexity.
Compartment models. Compartment models divide
the cardiac circulatory system into distinct spaces
(intravascular, interstitial, and intracellular). The
GdCA concentration varies among these compart-
ments over time as molecules move from 1 space to
another. Rate constants describe the movement
between any 2 compartments (Fig. 3). Such models
determine compartment concentrations and the
Figure 2. AMBF Calculation by Fermi Function Deconvolution
Myocardial time intensity curve (TIC) (left-most panel) equals the blood pool TIC (middle panel) convolved with (“X” symbol in circle)
the Fermi tr nsfer function (right-most panel). The maximum amplitude of the transf r function equals absolute myocardial blood flow
(AMBF). In this data from a dual-bolus study, the blood pool signal intensity (SI) values from the minibolus have been magnified by a
factor of 10 on the basis of the gadolinium (Gd) concentration ratio of the mini and full bolus (0.005/0.05 mmol/kg). The areas between
the dashed lines of the myocardial and blood pool TICs are used for analysis; these underwent correction for coil effects and baseline SI,
then conversion to Gd concentration before deconvolution. A.U. ! arbitrary units.
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tantly, the shape of the curve will be dependent on the
tissue blood flow as measured by the time curve Cp(t) of the
contrast agent blood plasma concentration entering the
tissue, also known as the arterial input function (AIF).
Ideally, the AIF should be a patient-specific measurement,
although standardized measurements have also been pre-
viously used.
Three-Compartment Model for DCE
To model DCE in the myocardium, an additional “trap-
ping” compartment is added to the two-compartment
model, as shown in Fig. 1. This trapping gives rise to the
altered kinetics that are observed in scarred myocardium.
The diffusive flux of contrast agent between the blood
plasma and EES, and between the EES and “trapping”




dt ! K1"Cp"t# " Ce"t## " K3"Ce"t# # Ctrap"t##, [1]
!trap
dCtrap"t#
dt ! K3"Ce"t# " Ctrap"t##, [2]
where K1 and K3 are the volume transfer constants (mea-
sured in min–1). The total tissue concentration of the con-
trast agent is the sum of the product of each compartment
and its respective fractional volume:
Ct"t# ! !pCp"t# # !eCe"t# # !trapCtrap"t#, [3]
where vp, ve, and vtrap are the volumes of distribution of the
bl od plas a, EES compartment, and the trapping com-
partment, respectively.
Simplifications ca be applied to Eq. [1], providing some
assumptions are made. The first assumption is that the
purpose f t odel is to describe DCE and not first-pass
perfusion. It is therefore assumed that contrast agent is
uniformly distributed throughout the body, meaning the
AIF is predominantly dependent on renal extraction. The
AIF is then assumed to be of a biexponential form:
Cp"t# ! D"a1e$m1t# a2e$m2t#, [4]
where a1, a2,m1, andm2 are constants, and D is the dose of
contrast agent per kilogram of body weight (mM/kg). This
assumption would not be reasonable over the first pass of
contrast agent, but it has been shown by Weinmann et al.
(13) that the AIF follows this form 1 min after contrast
agent administration. The second assumption is that the
rate of change of Ce(t) is predominantly dependent on K1.
This is based upon the observation that the perfusion
effects are fast compared to those of DCE, meaning that
K1 % K3. This allows Eq. [1] to be simplified to:
!e
dCe"t#
dt ! K1"Cp"t# " Ce"t##, [5]
which allows for an analytical solution to Ct(t), greatly
decreasing computational time. The third assumption is











where K2 and K4 are the rate constants (measured in min–1)
between the blood plasma and the EES, and between the
EES and the “trapping” space, respectively. The form of
Eq. [4] allows for an analytical solution to Eq. [5], which
can then be used to find a solution to Eq. [2]. The solution
to Eqs. [2] and [5] is derived as (see Appendix) a four
exponential equation:
Ct"t# ! D"d1e$m1t# d2e$m2t# d3e$K2t# d4e$K3t#, [8]
where the variables d1, d2, d3, and d4 are each functions of
some of the following: a1, a2, m1, m2, K1, K2, vp, K3, and K4.
The values of m1, m2, a1, and a2 are determined by fitting
Eq. [4] to the [Gd]-time curve from blood supply to the
tissue of interest.
Two-Compartment Model for DCE
Previous PET studies in have highlighted potential diffi-
culties in three-compartment model-fitting because of the
reduced reliability and identifiability of the fitted param-
eters, which can then lead to inaccuracies in the model. A
solution in PET is to introduce parameter constraints (14).
A variation of the model in Eq. [8] is to assume constant
values for K1 and K2. Focus in this case would be solely on
changes in the transfer between the EES and trapping
compartment, hence a two-compartmental DCE model.
FIG 1. Diagram of the three-compartment pharmacokinetic model.
The model contains the blood volume, extracellular space, and
“trapping” compartment.
















Figure 1.6. Magnetisation preparation schemes for T1-weighted MPI. 
“( ) saturation recovery, (b) inversion recovery, (c) magnetisation driven steady state”. 
(Kellman and Arai, 2007). 
 
The original method of tissue preparation for CMR myocardial perfusion imagin  was a 
form of inversion recovery (IR) (Figure 1.6b). In their comprehensive review of this 
topic, Kellman and Arai state, “IR approaches have the potential for increased dynamic 

















































































































































































burden above 10% may serve as a threshold at which revascularisation conveys prognostic 


































Table	1:	Patient	demographics				Baseline	Demographics	of	Patient	Cohort	(n=53)	Parameter	 Data	(%)	Male	 41(77.3)	Age,	years	 63.5	±	10.8						Range	 43	to	83	BMI,	kg/m2	 27.5		±	4.1	Previous	coronary	intervention		 14	(26.0)	Normal	LV	function	 49	(92.5)	Canadian	Cardiovascular	Society	Angina	Grading	Scale	No	pain	or	Atypical	Symptoms	 16	(30.2)						Class	1	 24	(45.3)						Class	2	 10	(18.9)						Class	3	 3	(5.7)						Class	4	 0	(0)	Baseline	Electrocardiogram						Q	wave	 4	(7.5)						Left	Bundle	Branch	Block	 3	(5.7)						Right	Bundle	Branch	Block	 1	(1.9)	Cardiovascular	Risk	Factors						Diabetes	 16	(30.2)						Dyslipidaemia	 44	(83.0)						Current	Smoker	 9	(17.0)						Hypertension	 35	(66.0)						Family	History	 20	(37.7)						Peripheral	Vascular	Disease	 3	(5.7)	Medications						Aspirin	 51	(96.2)						Clopidogrel	 19	(35.8)						Beta	Blocker	 35	(66.0)						Statin	 50	(94.3)						Angiotensin	enzyme	inhibitor	or										angiotensin	receptor	blocker	 32	(60.3)						Nitrate	 12	(20.7)		
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patient	basis	(CAD=Coronary	Artery	Disease)			 Coronary	Angiography/FFR	 Total	CMR	3D	Perfusion		 	CAD	–ve	 CAD	+ve	 		Test	Positive		 2	 31	 33		Test	Negative		 17	 3	 20		Totals		 19	 34	 53			 95%	Confidence	Interval		 Value	 Lower	Limit	 Upper	Limit	Prevalence	 0.642	 0.497	 0.765	Sensitivity	 0.912	 0.752	 0.977	Specificity	 0.895	 0.655	 0.982	
	 126	
Table	4b.	Sensitivity	and	specificity	of	CMR	vs.	coronary	angiography	and	FFR	on	




































































3D Perfusion vs FFR


































































































Bland-Altman of Interobserver variability for assesment of ischaemic volume






























Bland-Altman of Intraobserver variability for assessment of ischaemic volume











































































































Coronary	angiography	Treating	physicians	decided	the	clinical	management	of	patients	including	the	referral	for	invasive	angiography	based	on	the	clinical	MPS	report	and	all	other	clinical	information.	Data	from	this	study	were	not	released	to	treating	physicians.	Clinically	indicated	coronary	angiography	performed	within	8	weeks	of	MPS	were	reviewed	for	this	study.	X-ray angiograms were reported by an experienced cardiologist blinded to the 
other studies. Significant CAD was defined as ≥70% stenosis of a first-order coronary artery 








Patients		Of	the	46	patients	recruited,	one	was	excluded	because	of	a	technical	fault	during	the	CMR	study,	in	which	contrast	was	injected	too	early	preventing	acqusition	of	the	first	pass	perfusion	under	hyperaemia.	Forty	five	patients	(31	men,	mean	age	59)	thus	formed	the	population	for	analysis.  The indication for referral was diagnosis of CAD in 26 
patients (58%) without a prior history. In this population the pre-test likelihood of underlying 
CAD was 37.8% (95% CI 31.8-43.9%). Nineteen patients had a previous history of CAD with 
15 patients whom had previous documented myocardial infarction (Table	1). 39 patients 
experienced symptoms during CMR stress perfusion compared with 35 patients during MPS. 






































25. Plein S, Kozerke S, Suerder D, Luescher TF, Greenwood JP, Boesiger P, Schwitter J. 
High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of 
coronary artery disease. Eur Heart J. 2008 Sep;29(17):2148-55 








Table	1:	Patient	Demographics		Parameter	 Data	(%)	Number	 45	Male	 32(71.1)	Age,	years	 58.9	±	7.7						Range	 44	to	76	BMI,	kg/m2	 25.8		±	2.8	Previous	myocardial	infarction	 15	(33.3)	Previous	coronary	intervention		 16	(35.6)	Normal	LV	function	(EF>60%)	 41	(91.1)	Canadian	Cardiovascular	Society	Angina	Grading	Scale	No	pain	or	Atypical	Symptoms	 27	(60.0)						Class	1	 9	(20.0)						Class	2	 6	(13.3)						Class	3	 3	(6.7)						Class	4	 0	(0)	Baseline	Electrocardiogram						Q	wave	 7	(15.6)						Left	Bundle	Branch	Block	 5	(11.1)						Right	Bundle	Branch	Block	 1	(2.2)	Cardiovascular	Risk	Factors						Diabetes	 16	(35.6)						Dyslipidaemia	 41	(91.1)						Current	Smoker	 12	(26.7)						Hypertension	 38	(84.4)						Family	History	 22	(48.9)	Medications						Aspirin	 41	(91.1)						Clopidogrel	 7	(15.6)						Beta	Blocker	 27	(60.0)						Calcium	Channel	blocker	 5	(11.1)						Statin	 41	(91.1)						Angiotensin	enzyme	inhibitor	or										angiotensin	receptor	blocker	 33	(73.3)						Nitrate	 12	(17.8)								
	 165	
						





 Angiography – Significant Coronary Disease 
 Absent Present Total 
CMR + 3 16 19 
CMR - 13 1 14 
Total 16 17 33 
 
 Angiography – Significant Coronary Disease 
 Absent Present Total 
MPS + 6 16 22 
MPS - 10 1 11 




































































































































A cardiac-triggered B1 calibration scan was acquired as one transverse section through the 
middle of the left ventricle during end-diastole using a saturated double-angle method with a 
segmented echo-planar imaging readout in a single breath hold. This scan yields the B1 maps 
for each independent transmit channel (sequentially acquired in the same breathhold), and is 
	 182	
used to obtain the phase difference and power ratio of the RF transmit channels for 

































































































Table	2:	Pulse	sequence	parameters				 TGRE	 bSSFP		TR	 1.8ms	 2.2ms	TE	 0.70ms	 1.04ms	Flip	angle	 15°	 35°	RF	Shimming	 Yes	(local)	 Yes	(local)	Partial	Echo	,	Halfscan	(Partial	Fourier)	in	x-y	and	z	planes	
Yes	0.75/0.75	 Yes	0.75/0.75	














































































































1.	 BSSFP	 34.17	 27.11	
	 TGRE	 32.13	 25.42	
	 	 	 	
2.	 BSSFP	 31.53	 27.12	
	 TGRE	 29.33	 26.29	
	 	 	 	
3.	 TGRE	 27.78	 21.44	
	 BSSFP	 27.80	 21.67	
	 	 	 	
4.	 TGRE	 21.24	 16.55	
	 BSSFP	 26.92	 18.30	
	 	 	 	
5.	 TGRE	 24.10	 18.20	
	 BSSFP	 28.40	 21.90	
	 	 	 	
Mean	 TGRE	 26.9	 21.6	
	 BSSFP	 29.8	 23.2	
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1 stress* 115±24 2220±412 18.30 81±20 945±210 10.67 9.2 2.71 
 rest 113±27 2199±460 18.46 116±26 650±144 4.60 3.4  
          
2 stress 170±36 1780±330 9.47 146±29 1021±243 5.99 8.7 2.12 
 rest* 159±29 1602±313 9.08 111±22 440±97 2.96 4.1  
          
3 stress* 83±18 1690±331 19.36 66±15 580±106 7.79 12.5 2.98 
 rest 138±26 1637±362 10.86 125±26 490±99 2.92 4.2  
          
4 stress 137±35 1777±367 11.97 100±23 704±142 6.04 6.2 1.59 
 rest* 97±26 1616±369 15.66 122±27 520±102 3.26 3.9  
          
5 stress* 84±19 1804±391 20.48 64±16 684±121 9.69 11.6 2.42 
 rest 138±22 1832±393 12.28 125±23 489±94 2.91 4.8  
          
          
Mean Stress 118±37 1854±209 15.92±4,89 91±34 787±187 8.04±2.12 9.64±2.5 2.36±0.54 




















































































318 and microscopy was −0.26 (95% limit of agreement
319 −1.69 to 0.73) (Figure 6b).
320 Using ANOVA to compare the perfusion reserve using
321 the different techniques, there was no significant difference
322 between the quantitative CMR data, manual counting of
323 spheres and using confocal microscopy, (P = 0.84, R2 = 0.03).
324 Bonferroni post-hoc testing did not show any significant dif-
325 ference between the results derived from different tech-
326 niques (CMR and histology).
327 Discussion
328 This study has shown that dynamic contrast enhanced
329 myocardial perfusion CMR during dipyridamole-stress in
330 a murine model is feasible at 3 Tesla. MBF and MBF re-
331 serve estimates were derived in good agreement with the
332existing literature and the reference standard of micro-
333sphere injection.
334The use of first-pass dynamic contrast enhanced myo-
335cardial perfusion CMR in rodent models has only recently
336been reported. The studies published to date used differ-
337ent methods to acquire myocardial perfusion data and in
338all data were acquired under resting conditions only.
339Coolen et al [14] performed acquisitions on a 9.4 T Bruker
340animal scanner. Data acquisition extended over three
341heart-beats, with a temporal resolution of approximately
342400 ms and a 15 ms acquisition window within the cardiac
343cycle. Acquisition was feasible and detected reduced re-
344gional blood flow in an LAD ligation model. This study,
345however, did not attempt absolute quantification and com-
346parisons with the existing literature could not be made.
a
b
Figure 4 Confocal microscopy images. a. confocal images at stress, b. confocal images at rest.
Jogiya et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:62 Page 6 of 10
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318 and microscopy was −0.26 (95% limit of agreement
319 −1.69 to 0.73) (Figure 6b).
320 Using ANOVA to compare the perfusion reserve using
321 the different techniques, there was no significant difference
322 between the quantitative CMR data, manual counting of
323 spheres and using confocal microscopy, (P = 0.84, R2 = 0.03).
324 Bonferroni post-hoc testing did not show any significant dif-
325 ference between the results derived from different tech-
326 niques (CMR and histology).
327 Discussion
328 This study has shown that dynamic contrast enhanced
329 myocardial perfusion CMR during dipyridamole-stress in
330 a murine model is feasible at 3 Tesla. MBF and MBF re-
331 serve estimates were derived in good agreement with the
332existing literature and the reference standard of micro-
333sphere injection.
334The use of first-pass dynamic contrast enhanced myo-
335cardial perfusion CMR in rodent models has only recently
336been reported. The studies published to date used differ-
337ent methods to acquire myocardial perfusion data and in
338all data were acquired under resting conditions only.
339Coolen et al [14] performed acquisitions on a 9.4 T Bruker
340animal scanner. Data acquisition extended over three
341heart-beats, with a temporal resolution of approximately
342400 ms and a 15 ms acquisition window within the cardiac
343cycle. Acquisition was feasible and detected reduced re-
344gional blood flow in an LAD ligation model. This study,
345however, did not attempt absolute quantification and com-
346parisons with the existing literature could not be made.
a
b
Figure 4 Confocal microscopy images. a. confocal images at stress, b. confocal images at rest.






































































































































Table 2 Summary	of	3D	perfusion CMR	literature 		 	









study functional and anatomical information was obtained in a single
MR examination. The feasibility of 3D reconstruction and fusion of
both scans as well as the visualization of different myocardial layers
could be shown. Combined evaluation of 3D-MRCAwith 3D-CMRperfu-
sion had superior sensitivity at the cost of a loss in speciﬁcity when
compared to CMR-perfusion alone in a vessel-based approach.
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of	this	technique	in	seven	volunteers	and	demonstrated	similar	signal	characteristics	of	2D	single-slice	and	3D	imaging	(241).		A	novel	study	reported	the	use	of	bSSFP	for	3D	myocardial	perfusion	MRI,	using	no	magnetisation	preparation	but	maintaining	steady	state	by	continuous	application	of	the	bSSFP	kernel	throughout	the	scan	(287).	This	approach	was	feasible	and	demonstrated	good	signal	characteristics.	As	imaging	was	gated	to	mid-diastole,	the	acquisition	was	limited	to	either	single-slice	imaging	or	single-slab	3D	encoding,	and	the	read-out	duration	ranged	between	300	and	380	ms.	As	demonstrated	in	this	thesis,	bSSFP	imaging	has	some	advantages	including	favourable	signal	characteristics	(283).	It	was	also	feasible	to	perform	stress	perfusion	studies	with	similar	image	quality.	Unfortunately,	this	paper	has	shown	that	these	benefits	can	often	be	mitigated	by	artefacts	affecting	interpretation,	as	has	been	described	with	2D	perfusion	imaging	(296).			
Advantages	of	3D	Perfusion	CMR		Although	conventional	multi-slice	imaging	is	accurate	for	diagnostic	purposes,	the	selective	coverage	with	variable	gaps	between	slices	limits	its	comparison	with	other	whole-heart	CMR	measurements	including	cine	imaging	and	LGE.	Matching	a	stress	3D	perfusion	CMR	scan	with	the	corresponding	stack	of	LGE	images	may	improve	delineation	and	quantification	of	peri-infarct	ischaemia.			As	all	data	in	3D	myocardial	perfusion	CMR	are	acquired	in	a	single	cardiac	and	respiratory	phase,	it	is	robust	to	inter-frame	motion.	The	3D	acquisition	is	also	more	signal-to-noise	efficient	than	2D	imaging,	and,	as	all	data	are	acquired	in	the	same	shot,	fewer	compromises	regarding	cardiac	phase	are	necessary.	This	may	have	further	relevance	when	quantifying	perfusion	and	perfusion	reserve.			Improved	 coverage	 of	 inducible	 perfusion	 abnormalities	 observed	 in	 conditions	 of	microvascular	 dysfunction	 including	 diabetes	 and	 LV	 hypertrophy	 can	 help	 in	differentiation	 from	 epicardial	 obstructive	 IHD	 for	 the	 purpose	 of	 improved	 risk	stratification	(254).	
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	Two-dimensional	imaging	in	comparison	with	continuous	coverage	by	3D	imaging	has	been	shown	to	be	less	accurate	in	measuring	ischaemic	burden	(251).	In	clinical	practice,	ischaemic	burden	is	most	commonly	measured	by	MPS.	It	is	an	important	prognostic	factor	in	IHD	and	in	accordance	with	guidelines	(248)	(297)	may	help	identify	and	stratify	patients	who	will	benefit	most	from	revascularisation	compared	with	medical	therapy.			Compared	with	SPECT,	the	higher	resolution	of	3D	myocardial	perfusion	CMR	without	exposure	of	patients	to	ionising	radiation	make	the	latter	an	ideal	method	for	serial	imaging	and	to	assess	the	efficacy	of	treatment	designed	to	improved	regional	blood	flow	(298).		
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Background	 –	 First-pass	 myocardial	 perfusion	 cardiovascular	 magnetic	 resonance	(CMR)	 imaging	 yields	 high	 diagnostic	 accuracy	 for	 the	 detection	 of	 coronary	 artery	disease	(CAD).	However,	standard	2D	multi-slice	CMR	perfusion	techniques	provide	only	limited	 cardiac	 coverage	 and	 hence	 considerable	 assumptions	 are	 required	 to	 assess	myocardial	 ischemic	 burden.	 The	 aim	 of	 this	 prospective	 study	 was	 to	 assess	 the	diagnostic	performance	of	3D	myocardial	perfusion	CMR	to	detect	functionally	relevant	CAD	with	FFR	as	a	reference	standard	in	a	multi-center	setting.	
Methods	and	Results	–	A	total	of	155	patients	with	suspected	CAD	listed	for	coronary	angiography	 with	 FFR	 were	 prospectively	 enrolled	 from	 5	 European	 centers.	 3D	perfusion	CMR	was	acquired	on	3T	MR	systems	from	a	single	vendor	under	adenosine	stress	and	at	 rest.	All	CMR	perfusion	analyses	were	performed	 in	a	 central	 laboratory	and	 blinded	 to	 all	 clinical	 data.	 150	 patients	 were	 successfully	 examined	 (mean	 age	62.9+/-10	years,	45	 female).	The	prevalence	of	CAD	defined	by	FFR	(<0.8)	was	56.7%	(85	 of	 150	 patients).	 The	 sensitivity	 and	 specificity	 of	 3D	perfusion	 CMR	were	 84.7%	and	 90.8%	 relative	 to	 the	 FFR	 reference.	 Comparison	 to	 QCA	 (≥50%)	 yielded	 a	prevalence	of	65.3%,	sensitivity	and	specificity	of	76.5%	and	94.2%,	respectively.	
Conclusions	 –	 In	 this	multi-center	 study	3D	myocardial	perfusion	CMR	proved	highly	diagnostic	for	the	detection	of	significant	CAD	as	defined	by	FFR.	
	




	Myocardial	 perfusion	 imaging	 with	 cardiovascular	 magnetic	 resonance	 (CMR)	 yields	high	 diagnostic	 accuracy	 for	 the	 detection	 of	 coronary	 artery	 disease	 (CAD)1-8	 and	 its	prognostic	value	has	also	been	documented9-13.	 Standard	 two-dimensional	 (2D)	multi-slice	 perfusion	 CMR	 techniques	 have	 been	 compared	 with	 single	 photon	 emission	computed	 tomography	 (SPECT)	 in	 multi-center	 and	 single	 center	 trials2,	 5,	 7,	 14,	 15	confirming	the	high	diagnostic	accuracy	of	CMR	in	prospective	patient	cohorts.	Excellent	diagnostic	performance	has	been	documented	relative	to	hemodynamic	measurements	using	 fractional	 flow	 reserve	 (FFR)	 at	 1.5T	 in	 a	 single	 center	 setting16.	 A	 potential	limitation	of	 standard	2D	 techniques,	however,	 relates	 to	 the	 limited	 spatial	 coverage,	which	requires	geometrical	assumptions	for	the	quantification	of	ischemic	tissue	volume	to	 guide	 therapy	 as	 recommended	 by	 the	 recent	 European	 guidelines	 on	 myocardial	revascularization17.	Compared	with	methods	that	cover	the	whole	heart,	the	acquisition	of	 a	 limited	 number	 of	 slice	 may	 also	 affect	 the	 diagnostic	 performance	 as	 has	 been	indicated	previously	by	comparing	3D	versus	simulated	3-slice	2D	perfusion	imaging18.	In	order	 to	address	 the	 limited,	non-contiguous	 coverage	of	2D	multi-slice	myocardial	perfusion	CMR	techniques,	three-dimensional	(3D)	methods	have	been	developed	based	on	recent	advances	in	CMR	scan	acceleration	methodology19,	20.	Whole-heart	coverage	is	achieved	by	employing	data	undersampling	strategies	 in	conjunction	with	appropriate	image	reconstruction	 techniques21	such	as	(k-t)	 imaging	 including	sensitivity	encoding	(SENSE)19,	20,	22-24	 or	 principal	 component	 analysis	 (PCA)25.	 The	 diagnostic	 accuracy	 of	3D	 perfusion	 CMR	 has	 recently	 been	 validated	 in	 single-center	 studies	 against	 both	quantitative	 coronary	 angiography	 (QCA)18	 and	 FFR26	 in	 patients	 with	 known	 or	suspected	CAD.	Estimates	of	myocardial	ischemic	burden	from	3D	perfusion	CMR	have	
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Study	Population		The	 present	 prospective	 study	 was	 conducted	 at	 five	 European	 centers	 (University	Hospital	 Zurich,	 Switzerland;	 University	 Hospital	 RWTH	 Aachen,	 Germany;	 German	Heart	 Institute	Berlin,	Germany;	King's	College	London,	United	Kingdom;	University	of	Leeds,	United	Kingdom).	The	study	was	approved	by	the	local	ethics	review	boards	and	patients	were	prospectively	enrolled	upon	written	informed	consent.	Patients	scheduled	for	 diagnostic	 coronary	 angiography	 for	 the	 evaluation	 of	 suspected	 CAD	 were	consecutively	 recruited	 between	 November	 2011	 and	 August	 2013.	 Patients	 were	instructed	 to	 refrain	 from	 caffeine-containing	 substances	 24	 hours	 prior	 to	 the	examination.	Exclusion	 criteria	were	 standard	 contraindications	 for	CMR	 imaging	 (e.g.	incompatible	metallic	 implants	 and	 claustrophobia)	 and	 adenosine	 infusion	 (e.g.	 high	grade	atrio-ventricular	block	and	asthma).		
Cardiovascular	Magnetic	Resonance	Protocol		CMR	imaging	was	performed	with	the	patient	in	the	supine	position	using	3.0	Tesla	MR	systems	 (Philips	 Healthcare,	 Best,	 The	 Netherlands).	 Depending	 on	 the	 actual	 MR	scanner	version,	either	6-element	cardiac	or	28-element	torso	coil	arrays	were	used	for	signal	reception	and	cardiac	synchronization	was	performed	using	a	vector-ECG.	After	 the	 acquisition	 of	 standard	 cine	 scans	 for	 the	 assessment	 of	 left	 ventricular	function,	 3D	 myocardial	 perfusion	 CMR	 imaging	 was	 planned	 in	 short-axis	 geometry	with	full	left-ventricular	coverage.	Adenosine	was	administered	intravenously	at	a	dose	of	140µg/kg/min	under	continuous	monitoring	of	heart	rate	and	blood	pressure.	After	at	 least	 three	 minutes	 of	 adenosine	 infusion	 stress	 first-pass	 perfusion	 imaging	 (i.v.	
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bolus	application	of	0.075mmol/kg	b.w.	of	a	gadolinium-based	contrast	agent,	Gadovist,	Bayer	Healthcare,	Berlin,	Germany;	injection	rate	4.0ml/s	followed	by	20ml	saline	flush)	was	performed.	After	a	15-minute	waiting	period	for	equilibration	of	the	contrast	agent	within	the	myocardium,	the	identical	3D	myocardial	perfusion	CMR	scan	was	repeated	at	rest.	Dynamic	perfusion	data	were	acquired	in	every	heartbeat	over	30	cardiac	cycles	with	a	3D	saturation	prepared	spoiled	turbo	gradient	echo	sequence	(TR/TE/flip	angle	1.8ms/0.7ms/15°,	 saturation	pre-pulse	 delay	150ms,	 acquisition	 timed	 to	 end-systole,	75%	partial	Fourier	 sampling	 in	 two	directions	 including	an	elliptical	 k-space	 shutter,	10x	k-t	acquisition	with	49	training	profiles	resulting	in	a	net	acceleration	of	7x	and	an	acquisition	 window	 per	 heartbeat	 of	 200ms,	 k-t	 principal	 component	 analysis	reconstruction	 of	 16	 contiguous	 slices	 of	 5mm	 thickness,	 acquired	 voxel	 size	2.3x2.3mm2)20.	Perfusion	imaging	was	performed	during	a	single	inspiration	breathhold.	Shallow	 expiration	 was	 permitted	 in	 case	 the	 inspiration	 breathhold	 could	 not	 be	sustained	during	the	scan.	Using	this	approach,	data	acquisition	in	all	patients	suitable	for	CMR	exams	was	possible.			Following	 a	 further	 15-minute	 waiting	 period	 late	 gadolinium	 enhancement	 (LGE)	imaging	(0.15	mmol/kg	b.w.	cumulative	dose)	was	performed	in	the	identical	short-axis	geometry	 with	 a	 3D	 inversion	 prepared	 spoiled	 gradient-echo	 sequence	 (TR/TE/flip	angle:	3.6	ms/1.8	ms/15°,	voxel	size	1.6x1.6x10	mm3).	The	inversion	recovery	pre-pulse	delay	was	determined	using	a	Look-Locker	sequence	and	adjusted	accordingly.	Example	whole-heart	3D	myocardial	perfusion	CMR	images	acquired	during	adenosine	stress	and	at	rest	are	presented	in	Figure	1.		
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Visual	Assessment	of	Perfusion	Scans		CMR	images	were	analyzed	visually	in	a	central	data	analysis	lab	by	reviewers	blinded	to	clinical	 and	 angiographic	 patient	 data	 using	 a	 dedicated	 workstation	(ExtendedWorkSpace,	Philips	Healthcare,	Best,	The	Netherlands).		Overall	image	quality	of	stress	and	rest	perfusions	scans	was	graded	on	a	scale	between	1	 and	 4	 (1=	 non-diagnostic,	 2=	 poor,	 3=	 good,	 4=	 excellent).	 From	 all	 acquired	 image	slices	 the	 subset	 of	 short-axis	 slices	 with	 clearly	 identifiable	 left-ventricular	 cavity	enhancement	 during	 contrast	 agent	 passage	 and	 with	 >75%	 circumferential	 left-ventricular	 myocardium	 present	 were	 identified.	 The	 selected	 short-axis	 slices	 were	divided	into	6	equally	distributed	circumferential	segments	each	and	evaluated	visually.	Perfusion	defects	on	the	stress	perfusion	images	seen	in	any	segment	(≥1	segment)	with	≥25%	transmurality	persisting	 for	≥3	consecutive	dynamics,	which	were	not	visible	 in	the	rest	perfusion	scan	and	showed	no	enhancement	in	the	LGE	scan,	were	marked	to	be	pathologic	and	the	overall	study	was	considered	as	abnormal.		
Assessment	of	Myocardial	Ischemic	Burden		Myocardial	 ischemic	 burden	 (MIB)	 was	 estimated	 based	 on	 the	 quantification	 of	 the	tissue	 volume	 exhibiting	 myocardial	 hypo-enhancement	 using	 dedicated	 software	(GTVolume,	GyroTools	LLC,	Zurich,	Switzerland).	For	determination	of	myocardial	hypo-enhancement	 the	 dynamic	 frame	 of	 the	 stress	 perfusion	 scan	 showing	 the	 maximum	extent	 of	 regional	 hypo-enhancement	 during	 peak	 signal	 enhancement	 of	 remote	myocardium	 was	 selected	 19,20.	 In	 the	 presence	 of	 extensive	 ischemia-related	 hypo-enhancement	 (e.g.	 high	 grade	 triple	 vessel	 disease)	 remote	 myocardium	 either	represented	an	entire	myocardial	segment	or	its	subepicardial	layer.	The	left	ventricular	
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endo-	 and	 epicardial	 borders	 were	 manually	 identified	 in	 all	 slices	 to	 determine	myocardial	 volume.	 Quantification	 of	 hypo-enhanced	 tissue	 volume	 was	 performed	automatically	using	threshold-based	segmentation	with	a	signal	intensity	threshold	>2x	standard	 deviation	 (SD)	 below	 the	 signal	 of	 remote	 myocardium.	 Segmentation	 of	myocardial	 hypo-enhancement	 during	 stress	 is	 illustrated	 in	 Figure	 2	 for	 the	 patient	data	shown	in	Figure	1.		Total	 volumes	 of	 left	 ventricular	 myocardium	 and	 hypo-enhanced	 myocardium	 were	calculated	 using	 the	 disk	 summation	method.	Myocardial	 ischemic	 burden	 (MIB)	was	defined	 by	 the	 volume	 of	 hypo-enhancement	 normalized	 to	 total	 left	 ventricular	myocardial	 volume	 and	 is	 quoted	 in	 percentage.	 In	 case	 of	 concurrent	 presence	 of	myocardial	 scar	 as	 identified	 on	 LGE	 images,	 the	 amount	 of	 scar	 tissue	 volume	 was	calculated	based	on	segmentation	of	hyper-intense	tissue.	Subsequently,	the	scar	tissue	volume	was	subtracted	from	the	volume	of	hypo-enhancement	prior	to	MIB	calculation.		
Fractional	Flow	Reserve	and	Quantitative	Coronary	Angiography	Measurements			Fractional	 flow	 reserve	 (FFR)	was	measured	 using	 standard	methods28	with	 a	 0.014-inch	coronary	pressure	sensor–tip	wire	(Volcano	Therapeutics,	San	Diego,	California	or	Pressure-Wire	Certus,	St.	Jude	Medical	Systems	AB,	Uppsala,	Sweden)	in	vessels	visually	assessed	 by	 the	 angiographers	 as	 having	 ≥50%	 and	 ≤80%	 diameter	 stenosis	 in	 two	orthogonal	 views	 with	 ≥2mm	 luminal	 diameter.	 For	 the	 purpose	 of	 the	 study	 and	 in	accordance	to	guidelines,	stenoses	in	vessels	with	less	than	2mm	luminal	diameter	were	considered	non-significant29.	Coronary	stenosis	with	an	FFR	value	<0.8	were	classified	as	 hemodynamically	 relevant.	 Total/subtotal	 occlusion	 or	 high-grade	 stenosis	 (>80%	diameter	 stenosis)	 did	 not	 undergo	 pressure	 wire	 assessment	 and	 were	 considered	hemodynamically	significant.		
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Coronary	 angiography	was	 performed	 by	 routine	 techniques.	 At	 least	 two	 orthogonal	views	of	every	major	coronary	vessel	and	its	side	branches	were	acquired.	Quantitative	coronary	angiography	(QCA)	was	performed	off-line	by	an	independent	core	laboratory	being	blinded	to	the	results	of	CMR	imaging.		
	




Patient	Characteristics		The	 characteristics	 of	 the	 patient	 cohort	 are	 listed	 in	 Table	 1.	 Of	 the	 155	 recruited	patients,	2	studies	were	lost	due	to	data	storage	failure,	1	study	was	incomplete	because	of	patient	claustrophobia,	1	study	had	to	be	terminated	due	to	a	bronchospasm	during	adenosine	 infusion	and	1	study	was	 incomplete	because	of	an	unknown	ferromagnetic	splint	 in	 the	 chest	wall.	 Accordingly,	 a	 total	 of	 150	 patients	 (n=30	 from	 Zurich,	 n=30	from	Aachen,	n=32	from	Berlin,	n=31	from	London	and	n=27	from	Leeds;	n=105	(70%)	male;	 mean	 age	 62.9±10.0	 years,	 range	 33-83	 years)	 formed	 the	 final	 population	 for	analysis.	Table	2	lists	the	hemodynamic	data	recorded	during	the	CMR	examination.		
Diagnostic	Performance	The	prevalence	of	CAD	as	defined	by	FFR	<0.8	was	56.7%	(85	of	150	patients)	and	the	sensitivity	of	3D	perfusion	CMR	was	84.7%	(95%	CI:	75.3	to	91.6)	with	a	specificity	of	90.8%	(95%	CI:	81.0	to	96.5)	and	diagnostic	accuracy	of	87.3%	(95%	CI:	81.1	to	91.7).	Positive	 and	 negative	 predictive	 values	 were	 92.3%	 (95%	 CI:	 84.0	 to	 97.1)	 and	 81.9	(95%	CI:	71.1	to	90.0),	respectively.	The	prevalence	of	CAD	as	defined	by	QCA≥50%	was	65.3%	 (98	 of	 150	 patients).	 Analysis	 of	 3D	 CMR	 perfusion	 data	 with	 QCA	 as	 the	reference	standard	yielded	a	 sensitivity	of	76.5%	(95%	CI:	66.9	 to	84.5),	 specificity	of	94.2%	(95%	CI:	84.0	to	98.7),	and	diagnostic	accuracy	of	82.6%	(95%	CI:	75.8	to	87.9).	The	 positive	 predictive	 value	 was	 96.2%	 (95%	 CI:	 89.2	 to	 99.2)	 and	 the	 negative	predictive	value	was	68.1%	(95%	CI:	56.0	to	78.55).				
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	The	present	multi-center	study	has	assessed	the	diagnostic	performance	of	whole-heart	3D	myocardial	perfusion	CMR	for	the	detection	of	significant	CAD	as	determined	by	FFR	and	QCA.	The	main	 findings	of	 the	 study	are:	 (1)	3D	myocardial	perfusion	CMR	at	3.0	Tesla	is	a	robust	technique	for	the	detection	of	CAD	in	a	European	multi-center,	single-vendor	 setting;	 (2)	 the	diagnostic	 accuracy	of	 3D	myocardial	 perfusion	CMR	 to	detect	functionally	significant	CAD	is	high	and	confirms	previous	data	on	2D	multi-slice	and	3D	whole-heart	myocardial	 perfusion	CMR	using	 FFR	 as	 the	 reference	 standard16,	26,	28,	31;	and	 (3)	 the	 myocardial	 ischemic	 burden	 derived	 from	 3D	 whole-heart	 myocardial	perfusion	 CMR	 provides	 an	 accurate	 diagnostic	 tool	 for	 the	 detection	 of	 flow-limiting	CAD.		Relative	 to	 previous	 single-center	 (3T	 CMR)	 and	 dual-center	 (1.5T	 CMR)	 3D	 CMR	perfusion	studies	using	FFR	as	a	reference,	our	results	compare	well	for	sensitivity	and	specificity	 (85%	 vs.	 91%26	 vs.	 90%28	 and	 91%	 vs.	 90%26	 vs.	 82%28)	 demonstrating	robustness	of	the	method	also	in	a	European	multi-center	setting.	The	added	benefit	of	3D	 myocardial	 perfusion	 CMR	 over	 2D	 three-slice	 imaging	 for	 assessing	 MIB	 has	recently	 been	 indicated27.	 Furthermore,	 the	 high	 inter-study,	 intra-	 and	 inter-reader	reproducibility	 has	 been	 confirmed18,	 28.	 While	 the	 present	 multi-center	 study	 was	conducted	using	3.0T	CMR	systems,	the	protocol	is	readily	applicable	to	1.5T	machines	as	demonstrated	previously28.	Application	of	the	method	on	MR	systems	from	different	vendors	 is	possible	upon	modification	of	 the	pulse	sequence	and	image	reconstruction	software.	To	this	end,	the	image	reconstruction	code	is	provided	upon	request.		While	 previous	 single-center	 validation	 of	 three-slice	 2D	 approaches	 using	 1.5T	 CMR	systems	 yielded	 similarly	 high	 sensitivity	 and	 specificity	 relative	 to	 FFR18,	 the	assessment	of	ischemic	tissue	volume	was	not	possible	given	the	limited	coverage	of	2D	
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methods.	 As	 demonstrated	 previously,	 the	 diagnostic	 performance	 of	 3D	 perfusion	imaging	 compares	 favorably	 against	 simulated	 3-slice	 data	 extracted	 from	 the	 3D	volume18,	26.		According	 to	 current	 guidelines,	 the	 decision	 to	 perform	 coronary	 revascularization	procedures	 should	 be	 based	 on	 an	 objective	 documentation	 of	 myocardial	 ischemia	preferably	together	with	its	anatomical	localization	and	amount17.		Based	 on	 current	 and	 previous	 studies,	 3D	 myocardial	 perfusion	 CMR	 may	 prove	 a	valuable	alternative	to	methods	using	ionizing	radiation	to	monitor	and	guide	treatment.	CMR	 also	 allows	 imaging	 of	 at	 least	 the	 proximal	 coronary	 anatomy	 and	 fusion	 of	 3D	CMR	 perfusion	 with	 coronary	 CMR	 or	 low-dose	 coronary	 computed	 tomography	angiography	 (CCTA)	 offering	 promise	 for	 future	 comprehensive	 non-invasive	assessment	of	CAD33.	The	 amount	 of	 myocardial	 ischemia	 is	 a	 key	 factor	 to	 guide	 treatment	 decisions,	 i.e.	revascularization	is	recommended	in	case	myocardial	ischemic	burden	exceeds	10%30	of	total	 left-ventricular	 myocardium.	 However,	 these	 cut-off	 values	 were	 derived	 from	nuclear	 studies34,	 35	 and,	 although	 never	 directly	 compared,	 may	 not	 apply	 to	 2D	perfusion	 CMR	 in	 view	 of	 its	 limited	 cardiac	 coverage.	 Three-dimensional	myocardial	perfusion	 CMR	 and	 SPECT	 agree	well	 with	 the	 10%	 threshold27,	 highlighting	 another	potential	benefit	of	3D	whole-heart	versus	2D	multi-slice	myocardial	perfusion	CMR.	Today,	the	invasive	assessment	of	the	functional	significance	of	coronary	lesions	is	the	basis	of	therapeutic	decision-making36,	37,	even	though	FFR	measurements	are	invasive,	time-consuming	 and	 associated	 with	 radiation	 exposure	 rendering	 the	 method	 less	attractive	for	monitoring	patients.	To	this	end	and	based	on	the	evidence	presented	here	and	 elsewhere	 3D	 myocardial	 perfusion	 CMR	 may	 be	 considered	 a	 non-invasive	alternative	to	stratify	patients	according	to	guidelines.	
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Study	Limitations		An	 important	 limitation	 of	 the	 study	 design	 is	 that	 only	 patients	 who	 were	 already	scheduled	 for	a	 coronary	angiogram	were	 recruited	 in	 the	 study.	This	 fact	 reflects	 the	current	practice	of	referral	by	external	physicians.	In	line	with	current	guidelines	and	in	order	 to	 minimize	 complications	 of	 FFR	 measurements,	 hemodynamic	 assessments	were	only	performed	in	vessels	with	luminal	stenosis	of	50%	to	80%	at	angiography.	In	addition,	 the	 assessment	 of	 MIB	 was	 given	 as	 percentage	 ischemic	 myocardium	reflecting	 only	 relative	myocardial	 perfusion	 distribution	 at	 one	 particular	 time	 point	during	 the	 dynamic	 first-pass	 of	 the	 contrast	 agent.	 Accordingly,	 MIB	 is	 not	 a	 direct	measure	of	quantitative	myocardial	blood	flow.	It	is	furthermore	acknowledged	that	all	CMR	centers	involved	in	our	study	are	specialized	in	CMR	imaging	and	it	remains	to	be	demonstrated	how	the	technique	performs	at	sites	with	less	experience	and	expertise.			
Conclusion		This	multi-center	study	has	demonstrated	the	robustness	and	accuracy	of	3D	myocardial	perfusion	CMR	to	detect	functionally	significant	coronary	artery	disease	as	measured	by	FFR.			
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Appendix	Table	2b:	Inter-study	reproducibility	between	scans	1	and	3.	






Mean	Difference±SD	 0.19±1.54	 0.23±1.04	MPR	 Coefficient	of	Variation	 36.3%	 25.2%		
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Table	1:	Myocardial	perfusion	and	haemodynamics	for	the	subjects	during	each	of	the	three	scans.		
































































Mean	Difference±SD	 0.07±1.43	 0.07±1.03	MPR	 Coefficient	of	Variation	 33.5%	 23.9%		
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Table	3:	Mean	values,	intra-subject	differences	and	inter-study	reproducibility	for	LV	volumes	and	function.	
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Resolution	 	 	 	 	 	 	 	
Plein	2008	 51	 1.5-T	 5	x	k-t-SENSE	 1.4	mm	 4	slices	(NC)	 QCA>50%	 0.85*	
Plein	2008	 33	 1.5-T	 5	x	k-t	SENSE	 1.5	mm	 4	slices	(NC)	 QCA>50%	 0.80*	
	Plein	2008	 33	 3.0-T	 5	x	k-t	SENSE	 1.3	mm	 4	slices	(NC)	 QCA>50%	 0.89*	
Manka	2010		 20	 3.0-T	 8	x	k-t	SENSE	 1.1	mm	 3	slices	(NC)	 QCA>50%	 0.94*	
Motwani	2012	 100	 1.5-T	 8	x	k-t	BLAST	 1.6	mm	 3	slices	(NC)	 QCA	≥50%	 0.93*	
	Lockie	2011		 42	 3.0-T	 5	x	k-t	BLAST	 1.2	mm	 3	slices	(NC)	 FFR<0.75	 0.92*	
3-D	 	 	 	 	 	 	 	
Manka	2011	 146	 3.0-T	 6	x	k-t	SENSE	 2.3	mm	 16	slices	(WH)	 QCA	≥50%	 0.83†	
Manka	2012	 120	 1.5-T	 10	x	k-t	PCA	 2.0	mm	 16	slices	(WH)	 FFR<0.75	 0.87†	
Jogiya	2012	 53	 3.0-T	 10	x	k-t	PCA	 2.3	mm	 12	slices	(WH)	 FFR<0.75	 0.91†	
HYPR	 	 	 	 	 	 	 	
Ma	2012	 50	 3.0-T	 SW-CG-HYPR	 1.6	mm	 6	slices	(WH)	 QCA	≥50%	 0.90†	
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*	In	these	studies,	diagnostic	accuracy	was	calculated	by	receiver-operating	characteristic	analysis	and	expressed	as	area	under	the	curve.	†In	these	studies,	diagnostic	accuracy	was	expressed	as	the	proportion	of	correctly	classified	subjects	(true	positives	+	true	negatives)	among	all	subjects.	3-D	=	3-dimensional;	HYPR	=	highly	constrained	back-projection	reconstruction;	T=	Tesla;	SENSE	=	sensitivity	encoding;	BLAST	=	broad	linear	speed-up	technique;	PCA	=	principal	component	analysis;	SW-CG-HYPR=	sliding-window	conjugate-gradient	HYPR;	NC	=	non-contiguous;	WH=	whole-heart;	QCA	=	quantitative	coronary	angiography					
 	 358	
FIGURE	LEGENDS	
	
Figure	1	–	Dark-Rim	Artefact	A	60-year-old	man	with	suspected	angina	underwent	stress	perfusion	CMR	at	1.5-T	with	both	standard-resolution	(2.5mm	in-plane)	and	high-resolution	(1.5	mm	in-plane)	acquisition.	High-resolution	acquisition	was	facilitated	by	8-fold	k-t	BLAST	acceleration.	There	were	no	significant	stress-induced	perfusion	defects	seen	with	either	acquisition	(mid-ventricular	slices	shown)	but	there	was	significant	dark-rim	artefact	on	the	standard-resolution	images	(arrows).		Subsequent	X-ray	angiography	confirmed	normal	coronary	arteries.	CMR	=	cardiovascular	magnetic	resonance;	BLAST	=	broad	linear	speed-up	technique	
	
Figure	2	–	High-resolution	Perfusion	CMR	in	Multi-vessel	Disease	A	48-year-old	lady	with	suspected	angina	underwent	stress	perfusion	CMR	at	1.5-T	using	a	high-resolution	(1.4	mm	in-plane)	technique	facilitated	by	5x	k-t-BLAST.	Stress-induced	perfusion	defects	were	seen	in	all	three	territories	(arrows,	A,	B)	and	are	clearly	demarcated	as	subendocardial.	Subsequent	X-ray	angiography	revealed	significant	three-vessel	disease	(arrows,	C,	D).	This	case	highlights	the	ability	of	high-resolution	acquisition	to	overcome	the	potential	effects	of	balanced	ischemia	in	multi-vessel	disease	by	detecting	transmural	perfusion	gradients	and	subendocardial	ischemia.	CMR	=	cardiovascular	magnetic	resonance;	BLAST	=	broad	linear	speed-up	technique.				
Figure	3	–	Myocardial	Ischemic	Burden	Quantification	with	3D	Perfusion	CMR	Panel	(A)	shows	consecutive	slices	of	a	3D	perfusion	CMR	scan	during	adenosine	stress	in	a	patient	with	significant	stenoses	in	the	proximal	right	coronary	artery	and	distal	left	anterior	descending	coronary	artery.	Panel	(B)	shows	identical	images	illustrating	
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volumetry	of	myocardial	hypo-enhancement	using	a	signal	intensity	threshold	of	2	standard	deviations	below	remote	myocardium	(segmented	red	areas).	The	volume	of	myocardial	hypo-enhancement	was	30.4%	of	total	myocardium.	3D	=	3-dimensional;	CMR	=	cardiovascular	magnetic	resonance	
	
Figure	4	–	Case	Example	1	A	62	year-old	man	with	a	history	of	previous	bypass	surgery	10	years	ago,	re-presented	with	increasing	angina.	The	top	panel	dimensional	shows	3D	perfusion	CMR	at	stress	(2.5mm	in-plane	resolution,	12	slices);	the	middle	panel	shows	LGE	imaging	(1.5mm	in-plane	resolution)	and	the	bottom	panel	shows	high-resolution	stress	perfusion	CMR	(1.1mm	in-plane	resolution,	3	slices)	-		all	performed	on	the	same	patient	at	3.0-T.	Both	3D	perfusion	and	high-resolution	techniques	show	inferior	perfusion	defects	from	base	to	apex.	The	benefit	of	whole-heart	coverage	with	the	3D	technique	is	demonstrated	in	this	case,	as	hypoperfusion	is	seen	to	extend	beyond	the	scar	into	the	apical	cap	(top	panel,	arrows)	which	is	not	covered	by	the	three-slice	high-resolution	technique.	On	the	other	hand,	the	perfusion	defects	and	their	transmural	extent	are	better	delineated	with	the	high-resolution	technique	particularly	at	the	mid-ventricular	level.	By	virtue	of	their	similar	in-plane	spatial	resolution,	it	is	easier	to	correlate	LGE	images	with	high-resolution	perfusion	CMR	on	a	per	slice	basis,	compared	to	the	3D	technique.	CMR	=	cardiovascular	magnetic	resonance;	3D	=	3-Dimensional;	LGE	=	late-gadolinium	enhancement.	
Figure	5	–	Case	Example	2	A	45	year-old	man	with	previous	PCI	to	the	LAD	re-presented	with	significant	angina.	The	top	panel	dimensional	shows	3D	perfusion	CMR	(12	slices)	at	stress;	the	middle	panel	shows	LGE	imaging	and	the	bottom	panel	shows	high-resolution	(1.1mm	in-plane)	
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stress	perfusion	CMR	-	all	performed	at	3.0-T.	3D	perfusion	CMR	shows	stress-induced	hypo-perfusion	throughout	the	anterior	wall	from	base	to	apex	–	i.e.	well	beyond	the	area	of	scar	seen	in	the	mid-anterior	wall	on	LGE	imaging.			This	example	shows	the	benefit	of	whole-heart	coverage	with	the	3D	acquisition,	as	the	3-slice	high-resolution	techniques	did	not	demonstrate	any	significant	ischemia	beyond	the	established	scar	in	the	mid-ventricle.	X-ray	angiography	confirmed	a	sub-total	occlusion	of	a	large	diagonal	branch,	accounting	for	the	anterior	ischemia	(black	arrow).	CMR	=	cardiovascular	magnetic	resonance;	3D	=	3-Dimensional;	LGE	=	late-gadolinium	enhancement;	VLA	=	vertical	long	axis.	
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Figure	6	–	Case	Example	3	A	57	year-old	man	presented	with	worsening	angina	after	a	myocardial	infarction	6	months	ago.		The	top	panel	dimensional	shows	stress	3D	perfusion	CMR	(12	slices);	the	middle	panel	shows	LGE	imaging;	and	the	bottom	panel	shows	high-resolution	(1.1mm	in-plane)	stress	perfusion	CMR		-		all	performed	at	3.0-T.	Both	3D	perfusion	and	high-resolution	perfusion	techniques	show	an	inferior	perfusion	defect	from	base	to	apex	consistent	with	the	infarction	seen	on	LGE	imaging.	However,	the	perfusion	defects	are	better	delineated	at	high-resolution	and	a	small	amount	of	peri-infarct	ischemia	can	be	seen	in	each	of	the	3	slices	(arrows)	beyond	the	established	scar	on	corresponding	LGE	images.		With	3D	acquisition,	the	lower	spatial	resolution	(2.5mm	in-plane)	means	that	the	borders	of	the	perfusion	defect	within	each	slice	are	less	distinct	and	are	more	difficult	to	distinguish	from	dark-rim	artefact	in	the	mid	to	apical	anteroseptal	regions	(endocardial	border	opposite		dashed	lines).	CMR	=	cardiovascular	magnetic	resonance;	3D	=	3-Dimensional;	LGE	=	late-gadolinium	enhancement;	VLA	=	vertical	long	axis.		
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Figure	7	–	Case	Example	4		The	top	panel	dimensional	shows	stress		3D	perfusion	CMR	(12	slices);	the	middle	panel	shows	LGE	imaging;	and	the	bottom	panel	shows	high-resolution	(1.1mm	in-plane)	stress	perfusion	CMR		-		all	performed	at	3.0T.		The	3D	technique	demonstrated	significant	stress-induced	hypoperfusion	in	the	inferior	wall	from	base	to	apex	and	extending	into	the	basal	inferolateral	segments;	but	there	was	also	significant	dark-rim	artefact	in	the	septum	(endocardial	border	opposite	dashed	lines).	X-ray	angiography	confirmed	total	occlusion	of	the	mid	left	circumflex	artery	(arrow).	Due	to	the	sparsity	of	coverage,	the	3-slice	high-resolution	technique	only	detected	a	significant	perfusion	defect	at	the	mid-ventricular	level	and	therefore	significantly	underestimated	the	ischemic	burden	in	this	case,	compared	to	the	3D	technique.		Additionally,	interpretation	of	the	apical	high-resolution	slice	is	difficult	as	it	is	significantly	more	diastolic	than	the	other	slices,	which	is	a	disadvantage	of	all	2-dimensional	acquisitions	which	employ	a	single-shot	technique.	By	comparison,	with	3D	perfusion	CMR	all	slices	are	acquired	at	the	same	point	in	the	cardiac	cycle	which	makes	it	easier	to	determine	the	extent	of	perfusion	defects	across	different	myocardial	sections.	CMR	=	cardiovascular	magnetic	resonance;	3D	=	3-Dimensional;	LGE	=	late-gadolinium	enhancement;	VLA	=	vertical	long	axis.		
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Figure	4	–	Case	1	
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Figure	5	–	Case	2	
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Figure	6	–	Case	3	
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	Figure	7	–	Case	4
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